In addition, sunitinib as tyrosine kinase inhibitor might not be able to work efficiently to inhibit HER2/neu which involved in the tyrosine kinase mediated regulation of mammary gland since HER2/neu does not well express in NMU-induced breast cancer. Here, ERBB2 is linked to breast cancer.